drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous T cells engineered with the non-viral Sleeping Beauty transposon system to express an anti-CD19 chimeric antigen receptor incorporating 4-1BB costimulatory and CD3ΞΆ activation domains, plus huEGFRt as a safety/selection tag; designed to mediate targeted cytotoxicity against CD19+ B-cell malignancies.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified using the Sleeping Beauty transposon to express an anti-CD19 chimeric antigen receptor with 4-1BB costimulatory and CD3zeta activation domains. Binding to CD19 on malignant B cells triggers T-cell activation, expansion, and targeted cytotoxic killing of CD19-positive cells; the huEGFRt tag enables selection, tracking, and potential antibody-mediated depletion for safety.
drug_name
TranspoCART19 (autologous anti-CD19 CAR T cells)
nct_id_drug_ref
NCT06378190